Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03676400
Other study ID # MP-CM-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2, 2018
Est. completion date July 24, 2019

Study information

Verified date August 2019
Source Medipost Co Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.


Description:

NGF-574H is a obtained by collection of paracrine factors secreted by human umbilical cord blood-derived mesenchymal stem cell that was exposed in vitro to an artificially designed environment mimicking alopecia state in hair follicles to prime the composition of the paracrine factors optimized for hair growth. This study is to assess and confirm whether NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date July 24, 2019
Est. primary completion date July 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Origin: Asian (Korean)

2. Age: adult from 18 to 60 years old

3. Sex: female (minimum 70) and male

4. Understanding of the language spoken in the research center: subjects able to read the documents they are presented with and to hold to what they are explained.

5. Social cover: subjects having medical coverage

6. Subjects whose state of health, at the moment of inclusion, (auto-questionnaires and medical examinations for the recruitment, selection and inclusion), are compatible with this type of study.

7. Subjects can be pursuit and observation during the study period.

8. Subjects have a "hair loss grade" as below criteria:

- BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3)

- For female: Ludwig grade: ? to ?

- For male: Norwood-Hamilton grade: III to IV

- Hair density by phototrichogram: 60 to 190 hair/cm2

- Telogen hair = 5%

9. Subject with hair length =3cm in the vertex region and intending to keep this minimum length during the whole study period.

10. Subject accepting the constraints of the phototrichogram technique, i.e. agreeing to have 1 shaved zone of 1.5cm2 on the scalp.

11. Subject agreeing not to apply any topical treatment (other than the investigational product) or take any oral product or nutritional supplementation, or have any diet known to improve scalp and/or hair qualities or reduce hair loss during the whole study period.

12. Subject agreeing to use a neutral shampoo (subject's own shampoo)

13. Subject agrees to have a tattoo on the scalp on phototrichogram evaluation area.

14. Subject presenting preferably with chestnut brown, dark or black hair (in order to avoid problems of contrast)

Exclusion Criteria:

1. Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency.

2. Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner.

3. Subject who cannot be contacted in case of emergency.

4. Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method.

5. Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia.

6. Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study.

7. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening)

8. Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...)

9. Subject following a long period (>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)

10. Subject following a short period (<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period.

11. Subject having a immunosuppressive and/or corticoids treatment during the 4 weeks preceding the screening period

12. Subject having dyed, bleached hair or with a permanent wave prior to study start.

13. Subject who have been exposed to excessive or intensive UV light (natural or artificial) prior to the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
conditioned media of umbilical cord blood-derived stem cells
Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Placebo
Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells

Locations

Country Name City State
Korea, Republic of Dankook University Hospital Cheonan Chung Nam

Sponsors (1)

Lead Sponsor Collaborator
Medipost Co Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean total hair density (hair/cm2) The hair density by phototrichogram for 24 weeks application, in comparison to initial value (baseline) and/or placebo product.
Measurement of hair density by phototrichogram (Canfield): change in mean total hair density (hair/cm^2)
Statistical analysis: Time and product effects (p<0.05)
0, 6, 12 and 24 weeks
Primary Compare visual assessment before and after cosmetic treatment Visual Assessment using the clinical picture by an investigator: 7 point score (-3 to 3) Visual assessment by a subject (Self-Assessment): 7 point score (-3 to 3) 0, 6, 12 and 24 weeks
Secondary Change in mean Telogen hair density Measurement of telogen hair density, in comparison to initial value (baseline) and/or placebo product. 0, 6, 12 and 24 weeks
Secondary Change in mean Anagen hair density Measurement of anagen hair density, in comparison to initial value (baseline) and/or placebo product. 0, 6, 12 and 24 weeks
Secondary Change in hair growth speed Measurement of hair growth speed, in comparison to initial value (baseline) and/or placebo product. 0, 6, 12 and 24 weeks
Secondary Change in hair diameter Measurement of hair diameter, in comparison to initial value (baseline) and/or placebo product. Measure hair diameter using electronic outside micrometer. 0, 6, 12 and 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A